Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BMXMFOTCMKTS:CHEOYNYSE:LHNASDAQ:NTRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMXMFbioMerieux$142.45$134.16$93.50▼$143.47$16.86B0.738 shsN/ACHEOYCochLear$96.71-1.7%$88.56$74.76▼$115.85$12.87B0.897,757 shs2,154 shsLHLabcorp$260.30+1.3%$248.19$198.96▼$264.03$21.51B0.81639,223 shs1.02 million shsNTRANatera$167.96-0.1%$158.92$92.14▼$183.00$22.96B1.741.42 million shs3.08 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMXMFbioMerieux0.00%0.00%+9.86%+13.06%+42.51%CHEOYCochLear-1.72%+4.18%+10.70%+16.08%-10.33%LHLabcorp+1.24%-0.66%+5.43%+13.30%+28.07%NTRANatera-0.12%-2.27%+4.19%+16.69%+50.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMXMFbioMerieuxN/AN/AN/AN/AN/AN/AN/AN/ACHEOYCochLearN/AN/AN/AN/AN/AN/AN/AN/ALHLabcorp4.2989 of 5 stars2.42.02.54.22.82.51.3NTRANatera1.304 of 5 stars1.52.00.00.03.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMXMFbioMerieux 3.00BuyN/AN/ACHEOYCochLear 2.67Moderate BuyN/AN/ALHLabcorp 2.79Moderate Buy$276.086.07% UpsideNTRANatera 3.00Buy$184.639.92% UpsideCurrent Analyst Ratings BreakdownLatest CHEOY, NTRA, LH, and BMXMF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025LHLabcorpBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingCautious ➝ Cautious6/25/2025LHLabcorpBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$250.00 ➝ $275.006/18/2025CHEOYCochLearUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/11/2025LHLabcorpMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$270.00 ➝ $283.005/15/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.005/12/2025LHLabcorpTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$274.00 ➝ $290.005/9/2025NTRANateraUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $218.005/9/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.005/7/2025BMXMFbioMerieuxRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold5/6/2025LHLabcorpPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$260.00 ➝ $280.004/30/2025LHLabcorpBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$240.00 ➝ $250.00(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMXMFbioMerieux$4.31B3.91$4.48 per share31.79$38.50 per share3.70CHEOYCochLear$1.49B8.50$2.33 per share41.51$9.21 per share10.50LHLabcorp$13.01B1.67$22.69 per share11.47$96.27 per share2.70NTRANatera$1.70B13.52N/AN/A$9.05 per share18.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMXMFbioMerieux$467.68MN/A0.00∞N/AN/AN/AN/A9/4/2025 (Estimated)CHEOYCochLear$233.99MN/A0.0040.46N/AN/AN/AN/A8/13/2025 (Estimated)LHLabcorp$746M$8.6530.0914.841.635.55%15.27%6.97%7/30/2025 (Estimated)NTRANatera-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)Latest CHEOY, NTRA, LH, and BMXMF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NTRANatera-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million4/29/2025Q1 2025LHLabcorp$3.73$3.84+$0.11$2.52$3.41 billion$3.35 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMXMFbioMerieuxN/AN/AN/AN/AN/ACHEOYCochLear$1.221.26%N/AN/AN/ALHLabcorp$2.881.11%N/A33.29%N/ANTRANateraN/AN/AN/AN/AN/ALatest CHEOY, NTRA, LH, and BMXMF DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/10/2025LHLabcorpquarterly$0.721.25%5/29/20256/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMXMFbioMerieux0.082.201.29CHEOYCochLearN/AN/AN/ALHLabcorp0.681.841.60NTRANateraN/A3.873.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMXMFbioMerieuxN/ACHEOYCochLearN/ALHLabcorp95.94%NTRANatera99.90%Insider OwnershipCompanyInsider OwnershipBMXMFbioMerieuxN/ACHEOYCochLearN/ALHLabcorp0.84%NTRANatera7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMXMFbioMerieux14,600118.36 millionN/ANot OptionableCHEOYCochLear5,155130.79 millionN/ANot OptionableLHLabcorp70,00083.70 million83.00 millionOptionableNTRANatera4,434136.55 million126.17 millionOptionableCHEOY, NTRA, LH, and BMXMF HeadlinesRecent News About These CompaniesArtemis Investment Management LLP Boosts Stake in Natera, Inc. (NASDAQ:NTRA)June 27 at 7:55 AM | marketbeat.comOppenheimer Asset Management Inc. Trims Stake in Natera, Inc. (NASDAQ:NTRA)June 27 at 4:03 AM | marketbeat.comHere's How Much $100 Invested In Natera 10 Years Ago Would Be Worth TodayJune 26 at 10:06 PM | benzinga.comStanley Druckenmiller's Updated Portfolio: 7 Top Stocks in 2025June 26 at 7:04 AM | money.usnews.com1 Volatile Stock to Own for Decades and 2 to Brush OffJune 26 at 7:04 AM | msn.comEnvestnet Portfolio Solutions Inc. Sells 2,578 Shares of Natera, Inc. (NASDAQ:NTRA)June 25 at 3:32 AM | marketbeat.comNatera, Inc. (NASDAQ:NTRA) Receives $184.63 Consensus Price Target from AnalystsJune 25 at 2:03 AM | americanbankingnews.comChevy Chase Trust Holdings LLC Acquires 16,678 Shares of Natera, Inc. (NASDAQ:NTRA)June 24, 2025 | marketbeat.comNarwhal Capital Management Has $1.41 Million Stake in Natera, Inc. (NASDAQ:NTRA)June 24, 2025 | marketbeat.comQ1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology StocksJune 23, 2025 | msn.com2,042 Shares in Natera, Inc. (NASDAQ:NTRA) Acquired by Whalen Wealth Management Inc.June 23, 2025 | marketbeat.comTrueMark Investments LLC Buys New Shares in Natera, Inc. (NASDAQ:NTRA)June 23, 2025 | marketbeat.comNatera, Inc. (NASDAQ:NTRA) Receives Average Rating of "Buy" from AnalystsJune 22, 2025 | marketbeat.com1,864 Shares in Natera, Inc. (NASDAQ:NTRA) Purchased by Institute for Wealth Management LLC.June 21, 2025 | marketbeat.com3 Reasons We Love Natera (NTRA)June 20, 2025 | msn.comNatera, Inc. (NASDAQ:NTRA) Shares Sold by Fifth Third BancorpJune 20, 2025 | marketbeat.comGuided Capital Wealth Management LLC Has $1.85 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)June 19, 2025 | marketbeat.comPrecision Wealth Strategies LLC Makes New $803,000 Investment in Natera, Inc. (NASDAQ:NTRA)June 16, 2025 | marketbeat.comElevation Point Wealth Partners LLC Sells 1,616 Shares of Natera, Inc. (NASDAQ:NTRA)June 16, 2025 | marketbeat.comHere's How Much You Would Have Made Owning Natera Stock In The Last 10 YearsJune 13, 2025 | benzinga.comHarbor Capital Advisors Inc. Sells 4,030 Shares of Natera, Inc. (NASDAQ:NTRA)June 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden Dome3 Blockchain Stocks to Profit in a Decentralized WorldBy Chris Markoch | June 24, 2025View 3 Blockchain Stocks to Profit in a Decentralized WorldScience Applications International Is a Wicked Hot Buy in JuneBy Thomas Hughes | June 9, 2025View Science Applications International Is a Wicked Hot Buy in JuneForget the Fed: Home Depot Is the Real Gauge of the U.S. ConsumerBy Jeffrey Neal Johnson | June 19, 2025View Forget the Fed: Home Depot Is the Real Gauge of the U.S. ConsumerGeospace Stock Skyrockets After Major Petrobras ContractBy Jeffrey Neal Johnson | June 24, 2025View Geospace Stock Skyrockets After Major Petrobras ContractCHEOY, NTRA, LH, and BMXMF Company DescriptionsbioMerieux OTCMKTS:BMXMF$142.45 0.00 (0.00%) As of 06/26/2025bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.CochLear OTCMKTS:CHEOY$96.71 -1.69 (-1.72%) As of 06/27/2025 03:55 PM EasternCochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.Labcorp NYSE:LH$260.30 +3.32 (+1.29%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$260.52 +0.23 (+0.09%) As of 06/27/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.Natera NASDAQ:NTRA$167.96 -0.21 (-0.12%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$167.50 -0.47 (-0.28%) As of 06/27/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
